U.S. flag

An official website of the United States government, Department of Justice.

Prescription Drug Monitoring Program: New York State Profile (2021)

NCJ Number
303736
Date Published
2021
Length
13 pages
Annotation

The Prescription Drug Monitoring Program Training and Technical Assistance Center (PDMP TTAC) reports 2020 data and 2021 features of the New York state Prescription Drug Monitoring Program (PDMP).

 

Abstract

The acronym for the New York PDMP is I-STOP. It is administered by the New York State Department of Health/Bureau of Narcotic Enforcement. The email address is provided, along with the URLs of the PDMP website and related websites for enrollment, query, data upload, and statistics. Contact information is provided for the Director and Deputy Director. In 2020, the state population was 20,215,751, and there were 125,159 DEA-registered prescribers and 5,513 DEA-registered dispensers. A total of 14 types of reports are available from the PDMP. Funding of the PDMP is provided by a CDC grant. The budget amount for 2021 is not reported. There are six staff members performing operational, technical, and analytical/epidemiological responsibilities. Key dates are reported for the establishment and development of the PDMP, and access information is provided for statutes and rules pertinent to the PDMP’s establishment and operations. Miscellaneous capabilities and policies are indicated, including the ability to de-identify data and the authority to release such data. There is a data retention policy that purges patient information and retains de-identified data. Training in the features and use of the PDMP is available but not required for prescribers. Information required for a PDMP account is outlined. A subpoena and written request are necessary for law enforcement personnel to obtain patient information in the PDMP. Information needed for a query is also indicated. Prescribers, but not dispensers, are required to provide drug data to the PDMP. Veterinarians are required to report their drug prescriptions to the PDMP but are not permitted to query. Data monitored or accessible pertain to drugs listed in Schedules II-V, medical marijuana dispensings, and pharmaceutical manufacturers/distributors sales. Technology features and authorized reports and their recipients are indicated. 

 

Date Published: January 1, 2021